Immune checkpoint blockade for advanced non-small cell lung cancer: challenging clinical scenarios

Area of Science:

• Oncology
• Immunology

Background:

• Immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 and CTLA-4 have demonstrated significant anti-tumour activity in advanced non-small cell lung cancer (NSCLC).
• Approved agents like nivolumab, pembrolizumab, and atezolizumab offer improved response rates, overall survival (OS), and quality of life (QoL) compared to chemotherapy.
• Despite their efficacy, novel challenges arise in clinical practice regarding their application.

Purpose of the Study:

• To highlight clinical challenges associated with immune checkpoint blockade therapy in NSCLC.
• To review rare immune-related adverse events (AEs) and discuss optimal treatment duration and patient selection.
• To address real-world clinical scenarios, including treatment re-challenge and management of immune-related AEs.

Main Methods:

• Case series presentation.
• Review of immune-related adverse events (AEs).
• Discussion of clinical scenarios and management strategies.

Main Results:

• Immune checkpoint inhibitors offer survival benefits in advanced NSCLC.
• Rare immune-related adverse events require careful management.
• Optimal patient selection and treatment duration are crucial for maximizing benefits and minimizing risks.

Conclusions:

• Immune checkpoint blockade represents a significant advancement in advanced NSCLC treatment.
• Addressing clinical challenges, including rare AEs and specific patient scenarios, is essential for effective utilization.
• Further research and clinical experience are needed to fully optimize the use of these novel immunotherapies.